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Abstract
Objectives: To assess the outcome of patients who develop a parapneumonic
effusion in the hospital while receiving appropriate antibiotic treatment. In the ever-
changing field of medicine, it is important and necessary to have up-to-date information
about new practice methods. Treatments often carry risks, and physicians need to weigh
the balance between the potential for doing good and the potential for harm. Community-
acquired pneumonia (CAP) is the leading cause of death from infectious diseases and the
sixth-ranked cause of death overall in the United States. Diagnostic and therapeutic
approach to patients with CAP may be now regarded of public health-importance
knowing that 4 to 5 million cases of CAP occur annually, accounting for approximately
l0 million physician visits, 500,000 hospitalizations, 45,000 deaths, and an annual cost
of $23 billion dollars.
Design, setting and patients: Patients admitted to University of Connecticut
Health Center between January 1 st 1999 and December 31 st 2001 with a diagnosis of
community-acquired pneumonia was retrospectively identified from a medical record
search. Computer-based radiology reports were studied and patients with minimal or no
effusion on admission who subsequently developed a pleural effusion were included.
Measurements: One thousand twenty eight patients were admitted with the
diagnosis of community-acquired pneumonia. One hundred ninety one patients had
minimal or no effusion on the admission chest radiograph and subsequently developed a
pleural effusion based on the computer-based radiology reports. After reviewing all 191
chest radiographs, 12 were excluded as the chest radiograph was lost; another 151 were
excluded, as the chest radiograph did not definitively show an effusion, therefore leaving
28 patients to be included in the study. The parapneumonic effusion was detected at a
mean of 3 days after admission. Seventy-one percent of parapneumonic the effusions
were small (under the 1/3a of the hemithorax) and 29 % were moderate (under the 2/3ra
of the hemithorax. Twenty-two patients (79%) were alive at discharge and 6 (21%) died
during the hospital stay. Twenty four patients (86%) had improvement in their symptoms
related to the initial pneumonic episode. A total of 21 patients (75%) had radiographic
improvement of the pleural effusion while receiving antibiotic therapy; of whom 12
(43%) had complete resolution of the pleural effusion and 8 (29%) had a decrease in the
size of the pleural effusion at the follow-up CXR exam. The size of the effusion
increased during antibiotic therapy in 3 patients (11%); 2 of these 3 patients had a
complete resolution of their effusion at the follow-up and one patient was lost. The PPE
remained unchanged in 2 (7%) of the patients and both of them had a complete
resolution of their effusion at the follow-up. Only one patient out of the 5 patients whose
PPE increased or remained unchanged during antibiotic therapy had a history of CHF.
No association was found (p>0.05) between the size of the effusion developed under
antibiotic therapy and the outcome of the PPE at follow up (PPE improved or resolved
vs. unchanged or increased).
Results: Only 28 out of 1028 patients developed a parapneumonic effusion during
antibiotic therapy. The majority of patients had clinical (90%) or radiographic (75%)
improvement while receiving antibiotic only. None of the 20 patients followed after
discharge required aggressive therapeutic approach.
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Conclusion: Patients who are admitted to the hospital with a diagnosis of
pneumonia and develop a PPE under appropriate antibiotic therapy may not require
diagnostic or therapeutic thoracentesis for their PPE. We believe that the present study,
by demonstrating that thoracentesis becomes an unnecessary medical procedure in a
certain group of patients who develop PPE, may have further impact on both patient
comfort and health-care utilization related to the very common diagnosis of CAP.
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1. Introduction
In the ever-changing field of medicine, it is important and necessary to have up-
to-date information about new practice methods. Treatments often carry risks, and
physicians need to weigh the balance between the potential for doing good and the
potential for harm. New guidelines are published quite frequently for conditions
considered to be of public health importance; most of the time these guidelines
appropriately call for an escalated rather than a de-escalated treatment. For example, the
initial medical approach for patients with acute myocardial infarction became steadily
more aggressive over years, once the medical literature showed that such aggressive
intervention would improve the morbidity and mortality of these patients. Occasionally
the capacity of medicine to treat illness has prompted reconsiderations of basic concepts
of biomedical ethics, regarding when to begin, withhold, or stop the therapy2.
We have the ability to treat conditions that if left alone tend do little damage to
the person. The majority of elderly men, for example, are found to have elevated blood
levels of prostate-specific antigen (PSA). In such cases it would have been inappropriate
during their lifetime to operate and remove the gland because the procedure carries
risks3, would be costly and has a lengthy recovery phase4. In that instance an operation
may be considered unnecessary over-treatment. The challenge for physicians is to spot
those people for whom an operation to remove the prostate would be beneficial and to
provide alternative therapy to others. Similarly, a decision regarding artificial hip
replacement in a young person with bone disease is complicated. Most artificial hip
joints last only ten years, so if the person is young he or she may need repeated
operations. However, at the moment, the techniques used actually damage the bone, so
that it is unlikely a surgeon would be able to perform the procedure more than twice.
Delaying treatment for as long as possible may benefit the patients Therefore, knowing
when not to intervene in order to "protect" patients from unnecessary and excessive risk
is as important, if not more important, than knowing when to start an appropriate
treatment.
In this article we will attempt to identify the possible clinical (i.e. the presence
or absence of fever, chills, cough, purulent sputum and chest pain) and imaging data (i.e.
the size of pleural effusion) that may help health care providers in identifying and
perhaps deferring a medical procedure (i.e. diagnostic thoracentesis) that later would
prove to be medically unnecessary for patients with pneumonia who develop pleural
effusions.
2. Background
Despite recent advances in diagnosis and treatment, community-acquired pneumonia
(CAP) is still a common and potentially lethal infectious disease. CAP is the leading
cause of death from infectious diseases and the sixth-ranked cause of death overall in the
United States6. The age adjusted death rates for the 15 leading causes of death in the
United States as per latest CDC National Vital Statistics Reports7 is described in Figure

CAP in the United States, with a cost of approximately $9 billion dollars per year.
Cost-of-illness studies are necessary to provide a comprehensive estimate of a disease’s
impact on the health-care system. Although such studies do not directly assess
alternative treatment strategies, cost of illness data can be used to evaluate whether
current treatment (cost) patterns are consistent with clinical expectations of the patient
outcomes with high-quality care. However, the economic issues surrounding the costs of
treating pneumonia are critically important to the national health-care system.
The exact costs related to the inpatient and office visits related to the CAP are
described in the Tables and 2.
Table 1
Average Ann.:ual No ofCAP Visits |993:-:,-:15 (m mil]izms)
Age lysiei.ans’ Eneny
Group (y) Offi.s lp.armnts :.Dcpamcnts
65 0,589 0A58 0.048 1,09.5
A38 .0,798
All ages 3027 i.256 0,2(1 4,487
Table 2
Number Aver,,ge Average Tmt Cot ta:l: Cost of
A:: oI tgfl Cost of Stay MDC Stay + MD
Gr)up Diharges of Stay f Slay :(in billions) (in bill.ions) (in billions)
519,573 5.8 :2. $3.139 $0,.192 $3331
All ages ],1353.53 69 $6652 S7,,55:2 $0A97 ,9

While many PPE will resolve without specific treatment therapy other than antibiotic
therapy of the underlying pneumonia4, other PPE require an aggressive therapeutic
approach, to prevent or ameliorate empyema or complicated pleural effusion. This
aggressive therapeutic approach is called "thoracentesis" and represents the procedure by
which some of the pleural fluid is removed by inserting a needle in the pleural cavity.
Thoracentesis is associated with a certain risk of complications, out of which
pneumothorax (i.e. collection of air or gas in the pleural space of the lung, causing the
lung to collapse) is the most common. This complication is associated with increased
morbidity and hospital stay, as well as patient discomfort. It is established5 16 17, that the
incidence of thoracentesis-related pneumothorax varies between 3% and 19%, with
additional treatment (i.e. chest robes) needed in 3.6% of all thoracenteses representing
almost half of all patients (48%) in whom pneumothorax occurred. Therefore,
thoracentesis is not a procedure devoid of medical complications and appropriate
exclusion of patients that not need it is essential, both for the patient comfort and health-
care utilization.
The recent American College of Chest Physician (ACCP) consensus conference
on the medical and surgical management of PPEz stratifies the therapeutic intervention
based on the risk for a poor outcome. Based on the ACCP consensus conference, any
patient with a small to moderate free-flowing pleural effusion should have a diagnostic
thoracentesis performed.
Some patients with pneumonia who do not have a PPE at the time of
presentation to the hospital may develop one during the hospital stay. One expert has
suggested an aggressive approach to these patients, while another has suggested that
patients who develop a PPE while on therapy do not need a thoracentesis. In both cases,
the recommendations were made based on expert opinion. The appropriate therapeutic
approach of such effusions is yet to be decided as the current medical literature provides
only limited and controversial data. Therefore, our paper will review retrospectively the
outcome of patients who develop pneumonia and pleural effusions while admitted to the
hospital and receiving antibiotic therapy. It is not counterintuitive to speculate though
that patients who are admitted to the hospital with a diagnosis of pneumonia and develop
a pleural effusion under appropriate antibiotic therapy may not require further aggressive
diagnostic approach, proven they improve clinically throughout their hospital stay.
3. Methods
Patient Selection and Definitions
All patients admitted to the University of Connecticut Health Center between
January st 1999 and December 31 st 2001 with a discharge diagnosis of pneumonia were
retrospectively identified from a medical record search based on ICD coding for
pneumonia (ICD 486) and bacterial pneumonia (ICD 482.0 to 482.9). Computer-based
radiology reports for these patients were reviewed and patients with minimal (defined as
a pleural effusion that blunted the costo-phrenic angle only) or no effusion on the
admission chest radiograph (CXR) who subsequently developed a pleural effusion during
their hospital stay were selected for further study. For many individuals, especially those
with only a portable AP view, the findings were not reported as definitive. Nonetheless,
these patients were considered for further review to maximize sensitivity. Chest
radiographs of the selected patients were then examined by 2 pulmonary physicians
jointly. Only those unequivocally confirmed as having developed a parapneumonic
effusion (defined as a pleural effusion with an ipsilateral infiltrate) were considered for
inclusion in study. The last step of the screening process required confirmation of the
clinical diagnosis of pneumonia, for which we required the radiographic finding of a new
infiltrate and at least two of the following: fever or diaphoresis, cough, purulent sputum,
dyspnea, hypoxemia or pleuritic chest pain.
Clinical improvement was defined as improvement or resolution of the signs or
symptoms that the patient had on the admission to the hospital. The size of the effusion
was defined as small if it occupied less than one third of the hemithorax, moderate if it
occupied less than two-thirds and large if it occupied more than two-thirds of the
hemithorax. The effusion was considered improved when it either decreased in size or
resolved, as documented by subsequent CXR films.
Data collection
The following data were collected from the medical records: (1) Admission
data: age, gender, comorbidities, symptoms on admission, antibiotics received prior to
admission (if any); (2) In-hospital data: size of the effusion, antibiotics received during
the hospital stay, time when the antibiotics were started, thoracentesis or other drainage
procedure results (if any), number of days in the hospital; and (3) Post-discharge data:
CXR findings, requirement for further therapy of pleural disease, disposition (home vs.
facility), outcome (alive vs. deceased), follow up visit interval, cause of death (unrelated
or related to the parapneumonic effusion).
Statistical analysis
Descriptive data for continuous variables are presented as means + SD or
medians with range, when appropriate. Statistical comparisons of nominal variables were
made using Fisher’s exact test. Statistical significance was defined as a two-tailed value
ofp<0.05.
Analyses were done with software from the Statistical Package for the Social
Sciences (version 12; SPSS, Chicago, IL).
4. Results
Patient population
Based on the computer-based radiology reports of the 1,028 patients admitted
consecutively to the University of Connecticut Health Center with the diagnosis of
pneumonia, 191 individuals had minimal or no effusion seen at the time of admission
CXR but subsequently developed a pleural effusion. Of these, 12 were excluded as the
films could not be located; the two pulmonary physicians who reviewed all the films in
the study excluded another 151 CXR that did not unequivocally show an effusion,
leaving 28 patients included in the study (2.7%). The clinical characteristics of the
patients who developed a PPE under the antibiotic therapy are described in Table 3. The
mean patient age was 76+15 years (range 36-94) and 57% were female. Ninety-six
percent of the patients had at least one comorbid condition. Underlying pulmonary
disease was present in 8 patients (29%), congestive heart failure (CHF) in 6 patients
(21%), neoplastic disease in 7 patients (25%) and HIV-infection in 2 patients (7%).
Within 2 months prior to admission the CD4 counts of one of the HIV infected patients
was 134 cells/mm3 and the viral load of the other HIV infected patient was 67500
copies/ml. The presenting symptoms included fever in 18 patients (64%), productive
cough in 18 (64%), dyspnea in 14 (50%) and pleuritic chest pain in 1 patients (4%); 5
patients (18%) were hypoxic. Twenty six patients (93%) received antibiotics within 24
hours of admission to the hospital. Six patients (21%) had received antibiotics prior to
admission, and 4 patients (14%) continued the same class of antibiotic during the
hospital stay.
An etiologic diagnosis was assigned for 8 patients (29%) as follows: 2
Streptococcus pneumoniae, 3 Staphylococcus aureus, Pseudomonas aeruginosa,
Haemophilus influenzae and Influenza A. The diagnosis was based on blood culture in
2 patients (7%), on sputum culture in 5 patients (18%) and on both blood and sputum
culture in patient (4%).
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Table 3.
Clinical Characteristics of the Patients who developed a Parapneumonic
Effusion under the Antibiotic Therapy
Characteristics Data
Age, yr (range)
Female (%)
Comorbidities
COPD
Coronary disease
HTN
Chronic renal failure
Diabetes
HIV positive
Cancer
CVA and/or dementia
Reasons for hospital admission (any two of the
36-94
16 (57%)
8 (29%)
6(21%)
4(14%)
6(21%)
3 (%)
2 (7%)
7 (25%)
4(14%)
following):
Fever and/or chills
Productive cough
Dyspnea
Hypoxemia
Pleuritic chest pain
Antibiotic use
Hospital day number when the antibiotic was
started (% patients)
Time of development of the parapneumonic
18 (64%)
18 (64%)
14 (50%)
5 (18%)
1(4%)
1(93%)
effusion
Hospital day number (mean and range)
Size of the parapneumonic effusion
Small
Moderate
Type ofpneumonia
Unilobar
Multilobar
3(1-10)
20 (71%)
8 (29%)
11 (39%)
17(61%)
11
Chest radiograph andPPEfindings
The parapneumonic effusion was detected at median of 3 hospital days after the
hospital admission. A small effusion was detected in 20 patients (71%) and moderate in
8 patients (29%). A diagnostic thoracentesis was attempted in 5 (18%) cases and was
successful in 4 (14%).
The reasons for thoracentesis were as follows: Persistent fever in the presence
of a small pleural effusion (1 patient) and worsening dyspnea in the presence of an
increasing pleural effusion (4 patients). According to Light’s criteriaTM, 2 patients (50%)
had an exudative effusion and one patient (25%) had a transudative effusion; in one
patient the culture and gram stain of the pleural effusion were negative with the rest of
the data missing. According to the 2000 ACCP Guidelines2, the 2 exudative PPE were
considered to be associated with a moderate risk of poor outcome based on the pH value
or pleural space anatomy. The pleural fluid characteristics for the 2 patients with
exudative effusions were as follows: pH level of 7.0, white blood count (WBC) with
67% monocytes and negative pleural fluid culture (one patient); and LDH of 1307 U/L
and glucose level of 127 mg/dl (the other patient). All 4 patients who successfully
underwent thoracentesis had negative gram stains and cultures of the fluid. The amount
of fluid removed at thoracentesis was 35cc for the exudative effusion and 400 cc for the
transudative effusion. The patient whose pleural fluid chemistry was missing had 150 cc
fluid removed. The amount of the fluid removed was not explicitly mentioned in the
patient whose pleura! fluid results were mentioned above (pH 7.0 and WBC of 345
cells/ul).
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Patient outcomes
Twenty-two patients (79%) were alive at discharge and 6 (21%) died during the
hospital stay. Twenty four patients (86%) had improvement in their symptoms related to
the initial pneumonic episode. A total of 21 patients (75%) had radiographic
improvement of the pleural effusion while receiving antibiotic therapy; of whom 12
(43%) had complete resolution of the pleural effusion and 8 (29%) had a decrease in the
size of the pleural effusion at the follow-up CXR exam. The size of the effusion
increased during antibiotic therapy in 3 patients (11%); 2 of these 3 patients had a
complete resolution of their effusion at the follow-up and one patient was lost. The PPE
remained unchanged in 2 (7%) of the patients and both of them had a complete
resolution of their effusion at the follow-up. Only one patient out of the 5 patients whose
PPE increased or remained unchanged during antibiotic therapy had a history of CHF.
No association was found (p>0.05) between the size of the effusion developed under
antibiotic therapy and the outcome of the PPE at follow up (PPE improved or resolved
vs. unchanged or increased).
None of the 28 patients who developed a PPE under antibiotic therapy required
chest tube thoracostomy during the hospital stay or at the follow-up. Also, all but the 2
patients who were lost to follow had documented clinical improvement (follow-up range
13 days to more than a year). The 2 patients who did not receive antibiotics within 24
hours had complete resolution of their PPE at the follow up and clinically improved
during their hospital stay. The median hospital stay for all 28 patients was 12 days and
the median hospital stay for patients alive at discharge was 10 days.
Six patients (21%) died during the hospital stay; in 2 patients (7%) the pleural
13
effusion improved, in another 2 patients (7%) the pleural effusion remained stable and in
the last 2 patients (7%) the effusion increased in size prior to the patients’ death. The
causes of death for the 6 patients were as follows: gastro-intestinal hemorrhage (1
patient), chronic respiratory failure in a stable COPD patient who requested withdrawal
of the mechanical ventilation (1 patient) and aspiration pneumonia with cardio-
pulmonary arrest (1 patient). The other 3 patients died unexpectedly. An improvement in
their symptoms related to the initial pneumonic infection was documented in the medical
records before they died. The major acute events before their death were listed in the
electronic medical records as follows: gastro-intestinal hemorrhage (1 patient) and
aspiration-related cardio-respiratory arrest in a patient who had tracheostomy-dependent
chronic respiratory failure (1 patient) and fever with worsening congestive heart failure
in a patient who had end-stage renal disease hemodialysis dependent (1 patient).
Of the 22 patients alive at discharge from the hospital, 2 (7%) were lost to
follow up, therefore leaving 20 patients for follow up. One of these 2 patients underwent
diagnostic thoracentesis and was discharged to a chronic rehabilitation facility. The first
follow up visit after discharge occurred after 21 days for half of the patients. The follow-
up intervals for the patients alive at discharge, as documented in the electronic medical
records, are described in Table 4.
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Table 4
The Clinical Outcome of Patients with a PPE and Alive at Discharge from the Hospital
Patient
Number
1
2
3*
4
5
6
7
8
9
10"
ll
12
13
14
15
16
17
18
19"
20
21"
22
Size of the
PPE developed
during hospital
stay
Moderate
Small
Small
Small
Small
Moderate
Small
Small
Small
Small
Moderate
Small
Moderate
Small
Small
Moderate
Small
Small
Small
Small
Moderate
Small
Distribution of
the pneumonia
associated with
a PPE
Multilobar
Unilobar
Unilobar
Unilobar
Multilobar
Unilobar
Unilobar
Multilobar
Multilobar
Multilobar
Unilobar
Multilobar
Unilobar
Multilobar
Multilobar
Multilobar
Unilobar
Multilobar
Unilobar
Unilobar
Multilobar
Multilobar
Period of
follow-up (post-
discharged days)
> 1 year
19
> 1 year
> year
17
> year
56
249
> year
> 1 year
> year
25
> year
54
> year
78
13
33
15
> 1 year
Lost
Lost
Radiographic
evolution of the PPE
(during hospital stay
or at follow up)
Decreased in size
Unchanged
Resolved
Resolved
Decreased in size
Resolved
Decreased in size
Increased in size
Resolved
Decreased in size
Decreased in size
Resolved
Resolved
Resolved
Resolved
Resolved
Unchanged**
Resolved
Increased in size
Resolved
Decreased in size
Increased in size
* Denotes patients who underwent diagnostic thoracentesis.
** Denotes CXR findings during the hospital stay as the patient did not have
a follow-up CXR
None of the 20 patients followed after discharge required further diagnostic or
therapeutic interventions for the PPE that developed while receiving antibiotic therapy.
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5. Discussion
Currently, there are no recommendations as to what is the best therapeutic
approach of a PPE that develops during antibiotic therapy. The absence of such
recommendations impacts both patient comfort and health-care utilization. All previous
studies agree on the importance of appropriate antibiotic coverage. While some experts
believe that the development of pneumococcal empyema after initiation of proper
therapy is unusual9 (and therefore diagnostic thoracentesis in patients who develop a
PPE under antibiotic therapy may be unnecessary), others strongly recommend both
diagnostic and therapeutic thoracentesis at the earliest sign of development of pleural
fluid2.
None of the 20 patients followed after hospital discharge developed empyema,
requiring further aggressive diagnostic or therapeutic approach. We lost a total of 2
patients at follow up; one developed a small PPE and the other developed a moderate
PPE considered of moderate risk of poor outcome based on the diagnostic thoracentesis.
We cannot unequivocally affirm that none of them developed an empyema; however we
consider this possibility very unlikely, as both of them clinically improved during their
hospital stay and they were continued to be followed after the hospital discharge at a
chronic rehabilitation facility. Six patients died during their hospital stay. All of them
clinically improved during their hospital stay and after in-depth search of the electronic
medical records their death was considered not to be related to the presence of the PPE.
One of the patients that died had ESRD, CAD and valvular insufficiency and developed
fever 24 hours before his death; we believe that his death was also unlikely to be the
result of an empyema, as the size of the PPE was small and the rest of his symptoms (i.e.
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cough and dyspnea) that prompted the hospital admission resolved during the hospital
stay.
The CXR often worsens initially after the antibiotic therapy is started, with the
development of a pleural effusion. In our study, in a majority of patients (71%) the size
of the PPE decreased or resolved during the antibiotic therapy. The PPE in the rest of the
patients remained unchanged or increased during the in-hospital antibiotic therapy, only
to improve after the hospital discharge. These findings are in agreement with the 2001
ATS Guidelines for the Management of Adults with Community-acquired pneumonia2
that if the patient is showing an otherwise good clinical response, the CXR progression
may have no significance. In our study, none of the patients developed large PPE. One
potential explanation may be that large PPE are less likely to develop under appropriate
antibiotic therapy.
In summary, the most important findings of this study are that none of the 20
patients that developed a PPE while receiving antibiotic therapy and were followed after
hospital discharge developed empyema; therefore thoracentesis may not be required in
patients who develop a PPE under appropriate antibiotic therapy. In such circumstances,
close clinical follow up may benefit the patient more than an early aggressive therapy
that is associated with certain procedure-related risks.
Overall in our study, only 28 out of 1028 patients (2.7%) developed a PPE
while receiving antibiotic therapy. This low incidence of the PPE is most likely related to
the fact that we only selected patients who unequivocally developed a PPE during the
antibiotic therapy. This method of patient selection may slightly underestimate the
incidence of the PPE developed during the antibiotic therapy, but it also eliminates the
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chance of having patients with infiltrates only on the CXR that also improve with
antibiotic therapy (i.e. false positives).
The major limitation of our study is its retrospective design. The answer to
what is the best therapeutic approach to patients that developed a PPE during the
antibiotic therapy is yet to be ideally decided in a prospective setting. However, we
believe that prospective studies in patients who develop a PPE under antibiotic therapy
are difficult to perform because of the researcher’s ethical imperative to intervene if less
than optimal care is observed22.
6. Conclusions
So far, from our study, it appears that patients who are admitted to the hospital
with a diagnosis of pneumonia and develop a PPE under appropriate antibiotic therapy
may not require diagnostic or therapeutic thoracentesis for their PPE. We do not disagree
with an early aggressive therapeutic intervention if clinical presentation is suggestive of
such approach; we just recommend that certain category of patients to be closely
monitored rather than undergoing early thoracentesis, procedure not devoid of certain
risks and patient discomfort. We believe that the present study, by demonstrating that
thoracentesis becomes an unnecessary medical procedure in a certain group of patients
who develop PPE, may have further impact on both patient comfort and health-care
utilization related to the very common diagnosis of CAP. Our conclusion, despite
committing to a new and less invasive diagnostic approach for patients with CAP who
develop a PPE, is not in argument with the current medical practice; it rather
complements it, as clinical judgment will remain the most precious step for medical
18
practice.
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